Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 617
Filter
1.
BMJ Case Rep ; 17(6)2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38839400

ABSTRACT

Coccygodynia (pain of the coccygeal bone) can be treated locally with anti-inflammatory drugs, local steroid injections, surgical removal of the coccyx and, more recently, with radiofrequency thermal ablation. Complications, such as perforation of the colon, can occur as a consequence of the close relationship between the rectum and the sacrococcyx and with the heat from the thermal ablation expanding to the surrounding tissue causing delayed damage with severe consequences. The treatment of this complication requires the combined effort of the gastrointestinal surgeon as well as a gastroenterologist. In this case report, we describe the treatment of this complication and the clinical course after a perforation of the rectum due to thermal ablation of the coccyx to treat long-standing coccygodynia.


Subject(s)
Coccyx , Iatrogenic Disease , Intestinal Perforation , Radiofrequency Ablation , Rectum , Humans , Intestinal Perforation/etiology , Intestinal Perforation/surgery , Coccyx/injuries , Radiofrequency Ablation/adverse effects , Rectum/injuries , Rectum/surgery , Female , Low Back Pain/etiology , Middle Aged
2.
RMD Open ; 10(2)2024 May 09.
Article in English | MEDLINE | ID: mdl-38724261

ABSTRACT

OBJECTIVE: A comparison of cryoneurolysis or radio frequency (RF) with placebo in patients with facetogenic chronic low back pain (LBP) for patient global impression of change (PGIC), pain intensity, function and quality of life, with 1-year follow-up. DESIGN: Single-centre, single-blinded placebo-controlled randomised controlled trial. SETTING: Single-centre study. PARTICIPANTS: Inclusion from March 2020 to September 2022: consenting adults over 18 years of age, LBP>3 months, average Numeric Rating Scale LBP≥4 average last 14 days and a positive response to a diagnostic medial branch block (>50% pain reduction after 60 min). INTERVENTIONS: 120 patients were block randomised 1:1:1 to cryoneurolysis, RF or placebo of the medial branch nerves. Physical therapy was added after 4 weeks for all groups. MAIN OUTCOME MEASURES: Primary outcome was PGIC 4 weeks after the intervention. Secondary outcomes included pain intensity (Numeric Rating Scale, NRS), quality of life (Short Form 36, EQ-5D-5L), disability (Oswestry Disability Index), depression (Major Depression Inventory) and catastrophising (Pain Catastrophising Scale). Outcomes were measured at 4 weeks, 3, 6 and 12 months. RESULTS: There was no statistically significant difference in PGIC at 4 weeks between cryoneurolysis and placebo (risk ratio (RR) 2; 95% CI 0.75 to 5.33, p=0.17) and RF and placebo (RR 1.6; 95% CI 0.57 to 4.49, p=0.37), except PGIC for cryoneurolysis at 6-month follow-up (RR 5.1; 95% CI 1.20 to 22.03, p=0.03). No statistically significant differences were found in secondary follow-up endpoints. CONCLUSIONS: Denervation of the medial branch nerve by either cryoneurolysis or RF compared with placebo did not demonstrate significant improvement in PGIC, pain intensity, function and quality of life in patients with facetogenic chronic LBP at short-term or long-term follow-up. TRIAL REGISTRATION NUMBER: NCT04786145.


Subject(s)
Chronic Pain , Low Back Pain , Pain Measurement , Quality of Life , Radiofrequency Ablation , Humans , Low Back Pain/therapy , Low Back Pain/etiology , Low Back Pain/psychology , Male , Female , Middle Aged , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Chronic Pain/therapy , Chronic Pain/etiology , Chronic Pain/psychology , Treatment Outcome , Adult , Single-Blind Method , Cryosurgery/methods , Aged , Pain Management/methods
3.
BMC Gastroenterol ; 24(1): 152, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38698314

ABSTRACT

BACKGROUND AND AIM: Esophageal squamous cell neoplasia (ESCN) is predominant in Asia. Endoscopic mucosal resection and endoscopic submucosal dissection (ESD) have both been recommended worldwide, however the application of endoscopic radiofrequency ablation (RFA) for treatment of early superficial ESCN remains inconclusive. We conducted a meta-analysis to study the effectiveness of RFA for early superficial ESCN. METHODS: Three major bibliographic databases were reviewed for the enrollment of case series and cohort trials prior to August 23, 2023. We included adults diagnosed with early superficial ESCN who had been receiving endoscopic RFA or ESD if the treatments were available. Our focus was on the 12-month histological complete response rate (CR) and 3-month histological CR, as well as the acute and late postoperative adverse events (AEs) rate during the at follow-up periods. RESULTS: Nine studies were enrolled for qualitative synthesis of narrative review, with eight trials involving a total of 447 participants for analysis. The pooled 12-month and 3-month histological CR were 0.83 (95% CI, 0.59-0.94, I2 = 80%) and 0.74 (95% CI, 0.67-0.80, I2 = 0%), respectively. As for safety, the acute and late postoperative AEs were 0.11 (95% CI, 0.05-0.26, I2 = 68%) and 0.19 (95% CI, 0.14-0.26, I2 = 0%), respectively. In subgroup analysis, the incidence of bleeding, laceration and perforation after endoscopic RFA showed 0.06, 0.06 and 0.02, respectively. When compared with ESD, RFA showed lower acute AEs and late AEs without any obvious significance. CONCLUSIONS: For early superficial ESCN, endoscopic RFA achieved both higher 12-month complete remission and late complication postoperatively when compared to 3-month histological CR and acute AEs separately, while the stricture was encountered most commonly. The choice between endoscopic RFA and ESD remains inconclusive.


Subject(s)
Endoscopic Mucosal Resection , Esophageal Neoplasms , Esophageal Squamous Cell Carcinoma , Radiofrequency Ablation , Humans , Esophageal Neoplasms/surgery , Esophageal Neoplasms/pathology , Radiofrequency Ablation/adverse effects , Radiofrequency Ablation/methods , Endoscopic Mucosal Resection/adverse effects , Endoscopic Mucosal Resection/methods , Esophageal Squamous Cell Carcinoma/surgery , Esophageal Squamous Cell Carcinoma/pathology , Postoperative Complications/etiology , Postoperative Complications/epidemiology , Treatment Outcome
4.
BMC Cancer ; 24(1): 666, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38822264

ABSTRACT

BACKGROUND: Currently, there is no consensus on the treatment of recurrent hepatocellular carcinoma (HCC) after hepatectomy. It is necessary to assess the efficacy and safety of radiofrequency ablation (RFA) combined with iodine-125 seeds implantation (RFA-125I) in the treatment of recurrent HCC. METHODS: This study retrospectively analyzed the clinical data of patients with postoperative recurrence of HCC receiving RFA-125I or RFA treatment from January 2013 to January 2023. Both RFA and 125I seeds implantation were performed under dual guidance of ultrasound and CT. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were compared between the two groups. RESULTS: A total of 210 patients with recurrent HCC were enrolled in this study, including 125 patients in the RFA-125I group and 85 patients in the RFA group. The RFA-125I group showed a significantly better survival benefit than RFA group (median OS: 37 months vs. 16 months, P < 0.001; median PFS: 15 months vs. 10 months, P = 0.001). The uni- and multivariate analysis showed that RFA-125I was a protective factor for OS and PFS. There were no procedure-related deaths and no grade 3 or higher adverse events in both groups. CONCLUSIONS: RFA combined with 125I seeds implantation under dual guidance of ultrasound and CT is effective and safe for the treatment of HCC patients with recurrence after hepatectomy.


Subject(s)
Carcinoma, Hepatocellular , Hepatectomy , Iodine Radioisotopes , Liver Neoplasms , Neoplasm Recurrence, Local , Radiofrequency Ablation , Humans , Liver Neoplasms/surgery , Liver Neoplasms/radiotherapy , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/radiotherapy , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Iodine Radioisotopes/therapeutic use , Iodine Radioisotopes/administration & dosage , Hepatectomy/methods , Male , Female , Middle Aged , Retrospective Studies , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Aged , Adult , Combined Modality Therapy , Treatment Outcome , Tomography, X-Ray Computed
7.
J Cancer Res Ther ; 20(2): 651-657, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38687936

ABSTRACT

BACKGROUND: The feasibility and safety of enhanced recovery after surgery (ERAS) for percutaneous computed tomography (CT)-guided microwave ablation (MWA) for treating lung nodules remain unclear. METHODS AND MATERIALS: A total of 409 patients with lung tumors treated at the Department of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University from August 2020 to May 2023 were enrolled. Perioperative data, including baseline characteristics, operation time, postoperative pain score (visual analog scale [VAS]), hospitalization expenses, postoperative complications, total hospital stay, and patient satisfaction, were observed and recorded. RESULTS: No perioperative mortality occurred in either group and complete ablation was achieved in all patients. Patients in the ERAS group had significantly shorter hospital stays (P < 0.001), reduced operation times (P = 0.047), lower hospitalization expenses (P < 0.001), lower VAS scores (P < 0.001), and fewer complications (P = 0.047) compared with the traditional group. CONCLUSIONS: ERAS for percutaneous CT-guided MWA (ERAA) is safe, effective, and feasible for the treatment of lung nodules.


Subject(s)
Enhanced Recovery After Surgery , Lung Neoplasms , Microwaves , Tomography, X-Ray Computed , Humans , Male , Lung Neoplasms/surgery , Lung Neoplasms/pathology , Female , Microwaves/therapeutic use , Middle Aged , Retrospective Studies , Tomography, X-Ray Computed/methods , Aged , Postoperative Complications/etiology , Postoperative Complications/epidemiology , Length of Stay/statistics & numerical data , Surgery, Computer-Assisted/methods , Treatment Outcome , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Adult , Feasibility Studies , Operative Time
8.
J Cancer Res Ther ; 20(2): 712-717, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38687944

ABSTRACT

OBJECTIVE: To evaluate the safety and efficacy of microwave ablation (MWA) combined with percutaneous vertebroplasty (PVP) in the treatment of multisegmental (2-3 segments) osteolytic spinal metastases. MATERIALS AND METHODS: This study comprised a retrospective analysis of data from 20 patients with multisegmental (2-3 segments) osteolytic spinal metastases who received MWA combined with PVP. The visual analog scale (VAS) score, Oswestry Disability Index (ODI) score, Quality of Life Questionnaire-Bone Metastases 22 (QLQ-BM22), and local recurrence before and after the operation were measured. The occurrence of complications was observed to evaluate safety. RESULTS: All operations were completed successfully with no serious complications. Transient nerve injury occurred in two cases, but recovered after symptomatic treatment. The bone cement leakage rate was 13.9% (6/43). The mean baseline VAS scores were 7.25 ± 0.91 before treatment and 7.25 ± 0.91, 3.70 ± 1.12, 2.70 ± 0.73, 2.40 ± 0.68, 2.25 ± 0.71, and 2.70 ± 0.92 at 1 day, 1 week, 1, 3, and 6 months after treatment; all values were significantly lower (P < 0.001). The mean baseline ODI score decreased from 56.90 ± 9.74 before treatment to 41.90 ± 7.09, 38.10 ± 7.93, and 38.80 ± 10.59 at 1, 3, and 6 months after treatment, respectively; all values were significantly lower (P < 0.001). The average QLQ-BM22 baseline score decreased from 54.10 ± 5.36 before treatment to 44.65 ± 5.22, 43.05 ± 4.78, 42.30 ± 4.06, and 42.15 ± 5.47 at 1 week, 1, 3, and 6 months after treatment; all values were significantly lower (all P < 0.001). The postoperative survival time of all patients was >6 months. In three patients, four vertebral segments recurred 6 months after operation. CONCLUSION: MWA combined with PVP is a safe and effective treatment for multisegmental osteolytic vertebral metastases that can effectively relieve pain, improve spinal function, improve quality of life, and delay tumor progression. However, it is a long operation, necessitating good preoperative preparation and effective intraoperative pain relief measures.


Subject(s)
Microwaves , Quality of Life , Spinal Neoplasms , Vertebroplasty , Humans , Vertebroplasty/methods , Vertebroplasty/adverse effects , Female , Male , Spinal Neoplasms/secondary , Spinal Neoplasms/surgery , Spinal Neoplasms/therapy , Middle Aged , Microwaves/therapeutic use , Aged , Retrospective Studies , Treatment Outcome , Combined Modality Therapy , Adult , Pain Measurement , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Bone Cements/therapeutic use , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery
9.
Anticancer Res ; 44(5): 2219-2230, 2024 May.
Article in English | MEDLINE | ID: mdl-38677752

ABSTRACT

BACKGROUND/AIM: This study aimed to compare the oncological outcomes of proton beam radiotherapy (PBT) with those of radiofrequency ablation (RFA) for newly diagnosed hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This study included 323 patients who underwent PBT (n=40) or RFA (n=283) as a curative treatment for previously untreated HCC between October 2016 and June 2021. The primary endpoints were local progression and toxicity. RESULTS: The median follow-up was 3.4 years (range=1.1-5.7 years). In terms of portal vein tumor thrombosis, tumor size, alpha-fetoprotein, and prothrombin-induced by vitamin K absence-II, the PBT group had significantly more severe tumor burdens than those of the RFA group (p<0.0001, p<0.0001, p=0.0004, and p<0.0001, respectively). No significant difference was observed in cumulative local progression rate (10.4% in PBT vs. 7.8% in RFA at 3-years, p=0.895). Grade 3 or higher toxicity was reported in only one patient (0.4%) after RFA. Multivariable analysis demonstrated that treatment modality was not a significant prognostic factor for local progression (hazard ratio=1.05; 95% confidence interval=0.32-3.48; p=0.934). CONCLUSION: PBT demonstrated comparable local control with acceptable toxicity to RFA in newly diagnosed HCC. Therefore, PBT may be a valid alternative.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Proton Therapy , Radiofrequency Ablation , Humans , Carcinoma, Hepatocellular/radiotherapy , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/radiotherapy , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Female , Proton Therapy/adverse effects , Proton Therapy/methods , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Middle Aged , Aged , Adult , Treatment Outcome , Aged, 80 and over , Retrospective Studies
10.
Front Endocrinol (Lausanne) ; 15: 1355383, 2024.
Article in English | MEDLINE | ID: mdl-38628591

ABSTRACT

Purpose: Radiofrequency ablation (RFA) is an effective and safe modality for the treatment of thyroid nodules. Nodule rupture is a major complication of RFA. There is little known on the natural history of nodule rupture due to a lack of clinical experience and no consensus on its management. A comprehensive review of nodule rupture presentation, diagnosis, and management is needed. Methods: We report a case of nodule rupture and conduct a literature review. A total of 33 patients experiencing nodule rupture after RFA were included, and their clinical presentation, management, and outcomes were collected and analyzed. Results: Nodule rupture presents with acute swelling (90.3%) and pain (77.4%) within 7 months of RFA procedure, most commonly due to disruption of the anterior thyroid capsule (87%), and can be diagnosed with ultrasonography. Most ruptures can be managed conservatively, exemplified by our reported case. There are no reported cases of long-term sequalae. Conclusion: Nodule rupture is the second most common major complication of RFA. Based on the available evidence, we propose a treatment algorithm for nodule rupture and recommendations for future data collection to address gaps in our understanding of rupture etiology and effective management.


Subject(s)
Radiofrequency Ablation , Thyroid Nodule , Humans , Radiofrequency Ablation/adverse effects , Radiofrequency Ablation/methods , Thyroid Nodule/surgery , Treatment Outcome
11.
J Am Heart Assoc ; 13(9): e031795, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38664237

ABSTRACT

BACKGROUND: Transcatheter renal denervation (RDN) has had inconsistent efficacy and concerns for durability of denervation. We aimed to investigate long-term safety and efficacy of transcatheter microwave RDN in vivo in normotensive sheep in comparison to conventional radiofrequency ablation. METHODS AND RESULTS: Sheep underwent bilateral RDN, receiving 1 to 2 microwave ablations (maximum power of 80-120 W for 240 s-480 s) and 12 to 16 radiofrequency ablations (180 s-240 s) in the main renal artery in a paired fashion, alternating the side of treatment, euthanized at 2 weeks (acute N=15) or 5.5 months (chronic N=15), and compared with undenervated controls (N=4). Microwave RDN produced substantial circumferential perivascular injury compared with radiofrequency at both 2 weeks [area 239.8 (interquartile range [IQR] 152.0-343.4) mm2 versus 50.1 (IQR, 32.0-74.6) mm2, P <0.001; depth 16.4 (IQR, 13.9-18.9) mm versus 7.5 (IQR, 6.0-8.9) mm P <0.001] and 5.5 months [area 20.0 (IQR, 3.4-31.8) mm2 versus 5.0 (IQR, 1.4-7.3) mm2, P=0.025; depth 5.9 (IQR, 1.9-8.8) mm versus 3.1 (IQR, 1.2-4.1) mm, P=0.005] using mixed models. Renal denervation resulted in significant long-term reductions in viability of renal sympathetic nerves [58.9% reduction with microwave (P=0.01) and 45% reduction with radiofrequency (P=0.017)] and median cortical norepinephrine levels [71% reduction with microwave (P <0.001) and 72.9% reduction with radiofrequency (P <0.001)] at 5.5 months compared with undenervated controls. CONCLUSIONS: Transcatheter microwave RDN produces deep circumferential perivascular ablations without significant arterial injury to provide effective and durable RDN at 5.5 months compared with radiofrequency RDN.


Subject(s)
Kidney , Microwaves , Renal Artery , Sympathectomy , Animals , Microwaves/therapeutic use , Microwaves/adverse effects , Sympathectomy/methods , Sympathectomy/adverse effects , Renal Artery/innervation , Kidney/innervation , Kidney/blood supply , Sheep , Catheter Ablation/methods , Catheter Ablation/adverse effects , Time Factors , Disease Models, Animal , Blood Pressure/physiology , Female , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects
12.
Adv Ther ; 41(6): 2342-2351, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38656739

ABSTRACT

INTRODUCTION: Laser and radiofrequency ablation are two thermal ablation methods currently widely used to treat lower limb venous insufficiency. However, very few studies have been conducted on the use of microwaves, a form of thermal ablation, for the treatment of small saphenous vein (SSV) insufficiency. This study aimed to examine the efficacy and safety of endovenous microwave ablation (EMA) for the treatment of SSV insufficiency. METHODS: The clinical data of 126 patients (126 lower limbs) with SSV insufficiency (SSV trunk reflux time ≥ 500 ms on lower limb color Doppler ultrasound) treated at the Surgery Department of The Sixth People's Hospital of Zhuji from January 2020 to June 2022 were analyzed retrospectively; 64 patients underwent EMA and 62 underwent endovenous laser ablation (EVLA). The perioperative marker data [duration of surgery, duration of hospitalization, length of thermal ablation, duration of thermal ablation, number of incisions, and numerical pain rating scale (NPRS)], complication data [skin ecchymosis, skin burns, surgical site infection, paresthesia, deep vein thrombosis (DVT), and heat-induced thrombosis (EHIT)], venous clinical severity score (VCSS), chronic venous disease quality of life questionnaire (CIVIQ-20) before and 1, 3, 12 months after surgery, and SSV trunk occlusion rate at 12 months after surgery were compared between the two groups. RESULTS: No significant differences in the surgery or hospitalization durations were observed between the two groups. There were no significant differences in the length of the SSV that required thermal ablation between the two groups; however, the thermal ablation time was shorter in the EMA group than that in the EVLA group (6.14 ± 1.47 min vs 7.05 ± 1.16 min, P < 0.001). There were no statistical differences in the number of incisions, volume of tumescent solution used, or quantity of sclerosing foam used. The NPRS scores of the EMA group at 24 h and 72 h after surgery were significantly greater than those of the EVLA group (4.03 ± 0.98 vs 3.52 ± 1.28, P = 0.013; 3.78 ± 1.06 vs 3.15 ± 1.03, P = 0.001). Moreover, the two groups showed no significant difference in the NPRS score at 1 month (1.14 ± 0.84 vs 1.07 ± 0.75, P = 0.623). The EMA and EVLA group patients experienced similar postoperative complications. The VCSS and CIVIQ-20 score significantly improved at 1, 3, and 12 months after surgery. The VCSS and CIVIQ-20 scores were compared between the two groups at 12 months after surgery, and there were no significant differences (1.44 ± 0.63 vs 1.56 ± 0.56, P = 0.261; 24.24 ± 4.96 vs 25.19 ± 5.36, P = 0.304). There was no significant difference in the incidence of SSV trunk occlusion at 12 months after surgery between the two groups (95.31% vs 96.77%, OR 1.475; 95% CI 0.238-9.146, P = 1.000). CONCLUSION: EMA and EVLA are equally effective treatment methods for SSV insufficiency. EMA is associated with higher NPRS scores in the early postoperative period.


Subject(s)
Laser Therapy , Microwaves , Saphenous Vein , Varicose Veins , Venous Insufficiency , Humans , Female , Saphenous Vein/surgery , Male , Middle Aged , Laser Therapy/methods , Laser Therapy/adverse effects , Varicose Veins/surgery , Microwaves/therapeutic use , Retrospective Studies , Venous Insufficiency/surgery , Endovascular Procedures/methods , Treatment Outcome , Adult , Aged , Radiofrequency Ablation/methods , Radiofrequency Ablation/adverse effects , Catheter Ablation/methods , Catheter Ablation/adverse effects , Ablation Techniques/methods , Ablation Techniques/adverse effects , Quality of Life
13.
Sci Rep ; 14(1): 7620, 2024 04 01.
Article in English | MEDLINE | ID: mdl-38556580

ABSTRACT

Radiofrequency ablation (RFA) comparative efficacy of treatments using video-assisted thoracoscopic sympathectomy (VATS) in the long term remains uncertain in patients with palmar hyperhidrosis (PHH). This study aimed to compare the efficacy and safety of RFA and VATS in patients with PHH. We recruited patients aged ≥ 14 years with diagnosed PHH from 14 centres in China. The treatment options of RFA or VATS were assigned to two cohort in patients with PHH. The primary outcome was the efficacy at 1-year. A total of 807 patients were enrolled. After propensity score matching, the rate of complete remission was lower in RFA group than VATS group (95% CI 0.21-0.57; p < 0.001). However, the rates of palmar dryness (95% CI 0.38-0.92; p = 0.020), postoperative pain (95% CI 0.13-0.33; p < 0.001), and surgery-related complications (95% CI 0.19-0.85; p = 0.020) were lower in RFA group than in VATS group, but skin temperature rise was more common in RFA group (95% CI 1.84-3.58; p < 0.001). RFA had a lower success rate than VATS for the complete remission of PHH. However, the symptom burden and cost are lower in patients undergoing RFA compared to those undergoing VATS.Trial Registration: ChiCTR2000039576, URL: http://www.chictr.org.cn/index.aspx .


Subject(s)
Hyperhidrosis , Radiofrequency Ablation , Humans , Treatment Outcome , Thoracic Surgery, Video-Assisted/adverse effects , Hyperhidrosis/surgery , Radiofrequency Ablation/adverse effects , Sympathectomy/adverse effects , Hand
14.
J Long Term Eff Med Implants ; 34(3): 37-41, 2024.
Article in English | MEDLINE | ID: mdl-38505892

ABSTRACT

Persistent pain is one of the most frequent complications following total knee arthroplasty (TKA) and can be devastating for the patient's quality of life. The use of genicular nerve radiofrequency ablation (GNRFA) is prevalent regarding non-surgical treatment of knee osteoarthritis. However, it is controversial when employed for the management of residual pain after TKA. This study aims to evaluate the efficacy of GNRFA for the treatment of post-TKA chronic pain and to assess the potential benefits of its use. Twelve patients sustaining chronic pain after TKA underwent GNRFA treatment. The intervention included the superior medial genicular nerve, the superior lateral genicular nerve and the inferior medial genicular nerve. Visual analog scale (VAS) system was utilized for pain assessment at 1-week, 6-month, and 1-year follow-ups. Patients experiencing chronic knee pain derived from other or unspecified causes were excluded. Mean VAS score before the treatment was 8.3, while it ended up 2.3, 5.7, and 7.9 at the 1-week, 6-month, and 1-year follow-up, respectively. Some patients reported residual pain that they regarded more bearable than before the procedure at the 1-week evaluation, with no significant alterations in the 6-month reassessment. In 2 cases results at the 1-week follow-up were dissatisfying, however, this aided us in distinguishing the cause of the persistent pain. We were not able to conclude that GNRFA used for the treatment of chronic pain after TKA is as efficacious as in knee osteoarthritis pain. However, in some cases, it proved to be beneficial regarding discerning the etiology of the pain.


Subject(s)
Arthroplasty, Replacement, Knee , Chronic Pain , Osteoarthritis, Knee , Radiofrequency Ablation , Humans , Arthroplasty, Replacement, Knee/adverse effects , Osteoarthritis, Knee/surgery , Chronic Pain/etiology , Chronic Pain/surgery , Quality of Life , Knee Joint/surgery , Radiofrequency Ablation/adverse effects , Treatment Outcome
15.
Eur J Gastroenterol Hepatol ; 36(6): 750-757, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38555605

ABSTRACT

OBJECTIVE: The objective of this study was to evaluate the safety and effectiveness of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in the treatment of large hepatic hemangiomas (LHH) (5-9.9 cm in diameter). METHODS AND MATERIALS: This study retrospectively collected data from 82 patients with LHH treated at Chaoyang Central Hospital. The study analyzed the differences in postoperative efficacy, operative time, blood routine, liver and kidney function on the first day after surgery, postoperative hospitalization time and postoperative complications. RESULTS: There were statistically significant differences in indicators such as white blood cell count, alanine aminotransferase, aspartate aminotransferase and total bilirubin on the first day after surgery between the RFA group (39 cases) and the TACE group (43 cases) ( P < 0.001). Compared to RFA, LHH patients treated with TACE had a general complication rate of 39.5% (vs. 43.6%; P = 0.7), a procedure-related complication rate of 30.2% (vs. 59.0%; P = 0.009), an effective rate at 6-12 months postoperatively of 55.8% (vs. 82.1%; P = 0.01), an operating-time of 41.2 ± 14.9 min (vs. 100.8 ± 35.5 min; P < 0.001) and hospitalization costs of 17052.7 ± 1364.8 yuan (vs. 30952.1 ± 4327.6 yuan; P < 0.001). CONCLUSION: This study indicates that the efficacy of RFA in treating LHH is significantly superior to TACE. Microwave ablation and RFA appear to be safe treatments for LHH. The TACE group exhibited shorter operating-time, lower hospitalization costs and lower demands on cardiopulmonary function.


Subject(s)
Chemoembolization, Therapeutic , Hemangioma , Liver Neoplasms , Operative Time , Humans , Male , Female , Liver Neoplasms/therapy , Middle Aged , Retrospective Studies , Treatment Outcome , Hemangioma/therapy , Adult , Chemoembolization, Therapeutic/methods , Chemoembolization, Therapeutic/adverse effects , Radiofrequency Ablation/adverse effects , Radiofrequency Ablation/methods , Length of Stay , Aged , Postoperative Complications/etiology , Catheter Ablation/methods , Catheter Ablation/adverse effects , Time Factors , Tumor Burden
16.
Cancer Med ; 13(4): e7068, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38457235

ABSTRACT

OBJECTIVE: This study aimed to compare the clinical efficacy of laparoscopic liver resection (LLR) and radiofrequency ablation (RFA) in treating solitary hepatocellular carcinoma (HCC) of the hepatic caudate lobe. METHODS: Patients with hepatic caudate lobe HCC who underwent LLR or RFA at three hospitals in China between February 2015 and February 2021 were included. In total, 112 patients met the inclusion criteria, of whom 52 underwent RFA and 60 underwent LLR. The outcomes of the two groups were compared and analyzed using propensity score matching (PSM) method. RESULTS: There were no significant differences between the two groups in terms of sex, HBV/HCV positivity, AFP positivity (>100 ng/mL), tumor position, Child-Pugh score, or preoperative liver function tests (ALT, AST, TBIL, ALB, and PT) (p > 0.05). Compared to the LLR group, the RFA group had a shorter operation time, less intraoperative bleeding, and shorter postoperative hospital stay (p < 0.05). There was no statistically significant difference in overall postoperative complications between the two groups (p > 0.05). Despite the larger tumor size, the LLR group had better postoperative recurrence-free survival (RFS) (p = 0.00027) and overall survival (OS) (p = 0.0023) than the RFA group. After one-to-one PSM, 31 LLR patients and 31 RFA patients were selected for further analyses. The advantages of LLR over RFA were observed in terms of RFS (p < 0.0001) and OS (p = 0.00029). CONCLUSION: LLR should probably be recommended as the preferred method for solitary caudate lobe HCC.


Subject(s)
Carcinoma, Hepatocellular , Catheter Ablation , Laparoscopy , Liver Neoplasms , Radiofrequency Ablation , Humans , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Propensity Score , Retrospective Studies , Catheter Ablation/adverse effects , Catheter Ablation/methods , Treatment Outcome , Hepatectomy/adverse effects , Hepatectomy/methods , Radiofrequency Ablation/adverse effects , Laparoscopy/adverse effects , Laparoscopy/methods
17.
Obstet Gynecol ; 143(5): 612-618, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38422502

ABSTRACT

OBJECTIVE: To compare pregnancy outcomes after laparoscopic radiofrequency ablation and myomectomy. METHODS: The ULTRA (Uterine Leiomyoma Treatment With Radiofrequency Ablation) study is an ongoing multicenter prospective cohort study with longitudinal follow-up up to 5 years comparing outcomes of radiofrequency ablation with myomectomy in premenopausal women older than age 21 years with symptomatic uterine leiomyomas. Participants were queried every 6 months after surgery to assess the incidence of pregnancy and pregnancy outcomes. RESULTS: Among 539 women enrolled in ULTRA, a total of 37 participants (mean age at first pregnancy 35.0±4.7 years) conceived 43 times as of March 2023 (22 radiofrequency ablation, 21 myomectomy). The average length of follow-up time after all procedures was 2.5±1.0 years. The baseline miscarriage rate in the study population was 33.3%. In participants who underwent radiofrequency ablation, 9 of 22 pregnancies (40.9%, 95% CI, 20.3-61.5%) ended in first-trimester miscarriage, 11 resulted in live births (50.0%, 95% CI, 29.1-70.9%), one resulted fetal death at 30 weeks of gestation, and one resulted in uterine rupture during miscarriage treatment with misoprostol 10 weeks after radiofrequency ablation. Among the live births in the radiofrequency ablation group, 45.5% were by vaginal delivery. In the myomectomy group, 9 of 21 pregnancies (42.9%, 95% CI, 21.7-64.0%) ended in first-trimester miscarriage and 12 resulted in live births (57.1%, 95% CI, 36.0-78.3%). There were no significant differences in the likelihood of live birth or miscarriage between the study groups. CONCLUSION: Full-term pregnancy and vaginal delivery are achievable after radiofrequency ablation of leiomyomas. However, in this interim analysis, the miscarriage rate in both radiofrequency ablation and myomectomy groups was higher than expected for women in this age group. Long-term data collection in the ongoing ULTRA study aims to further understand pregnancy outcomes after radiofrequency ablation compared with myomectomy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT0210094.


Subject(s)
Abortion, Spontaneous , Laparoscopy , Leiomyoma , Radiofrequency Ablation , Uterine Myomectomy , Uterine Neoplasms , Pregnancy , Humans , Female , Adult , Young Adult , Uterine Myomectomy/adverse effects , Uterine Myomectomy/methods , Pregnancy Outcome , Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/etiology , Abortion, Spontaneous/surgery , Prospective Studies , Uterine Neoplasms/therapy , Leiomyoma/epidemiology , Radiofrequency Ablation/adverse effects , Laparoscopy/methods
19.
HPB (Oxford) ; 26(5): 682-690, 2024 May.
Article in English | MEDLINE | ID: mdl-38342647

ABSTRACT

BACKGROUND: Minimally Invasive thermal ablation (MITA) of liver tumors is a commonly performed procedure, alone or in combination with liver resection. Despite being a first-option strategy for small lesions, it is technically demanding, and many concerns still exist about local disease control. METHODS: Consecutive patients undergoing MITA from 1-2019 to 12-2022 were retrospectively enrolled. Risk factors of local recurrence were investigated through univariate and multivariable cox regression analysis. RESULTS: At the multivariable analysis of the 207 nodules undergoing MITA, RFA was associated with worse local Recurrence Free Survival (lRFS) than MWA (HR 2.87 [95 % CI 0.96-8.66], p = 0.05), as well as a concomitant surgical resection (HR 3.89 [95 % CI 1.06-9.77], p = 0.02). A concomitant surgical resection showed worse lRFS in the subgroup analysis of both HCC (HR 3.98 [95 % CI 1.16-13.62], p = 0.02) and CRLM patients (HR 2.68 [95 % CI 0.66-5.92], p = 0.04). Interestingly, a tumor size between 30 and 40 mm was not associated to worse lRFS. CONCLUSION: MWA may reduce the risk of local recurrence in comparison to RFA, while MITA associated to liver resection may face an increased risk of local recurrence. Further prospective studies are needed to confirm such results.


Subject(s)
Liver Neoplasms , Neoplasm Recurrence, Local , Humans , Liver Neoplasms/surgery , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Female , Middle Aged , Retrospective Studies , Risk Factors , Aged , Hepatectomy/adverse effects , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Minimally Invasive Surgical Procedures , Treatment Outcome , Catheter Ablation/adverse effects , Radiofrequency Ablation/adverse effects , Risk Assessment
20.
Ann Vasc Surg ; 103: 89-98, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38395347

ABSTRACT

BACKGROUND: To compare radiofrequency ablation (RFA) and cyanoacrylate closure (CAC) for large-diameter great saphenous vein (GSV) insufficiency between diameters of 12 and 16 mm. METHODS: This study is a single-center retrospective study. Subjects who underwent endovenous treatment with RFA (Group A) or CAC (Group B) for GSV insufficiency between June 2015 and June 2021 who were followed up for at least 2 years were included in the study. Subjects who had a 12-mm to 16-mm target vessel diameter and subjects with grade 3 and grade 4 reflux were included. Subjects' demographic data (age, sex), body mass indices, clinical, etiological, anatomic, pathophysiologic classification, GSV diameter, reflux grade, target vessel length, preoperative venous clinical severity score (VCSS), procedural time, postoperative first-day pain scores, postoperative 14th-day patient satisfaction scale, and postoperative complications were noted. In follow-up, subjects were evaluated with duplex ultrasonography and VCSS at 1, 6, 12, and 24 months. RESULTS: In total, 142 subjects were included (n = 71 for both groups). The mean GSV diameter was 13.21 ± 1.00 for Group A and 13.51 ± 0.97 for Group B. The groups did not differ in terms of age, sex, body mass index, clinical, etiological, anatomic, pathophysiologic classification, GSV diameter, reflux grade, target GSV length, preoperative VCSS, complications, postoperative 24-hr pain status or postoperative 14-day patient satisfaction scale (P > 0.05 for all comparisons). The procedure time was significantly shorter in Group B (34.68 ± 4.22 min for Group A vs. 22.59 ± 4.5 min for Group B, P = 0.001). In the 1-month and 6-month Duplex ultrasonography of the subjects, partial closure and patency rates in Group B were significantly higher than those in Group A (P = 0.003 and P = 0.025, respectively). At the 12-month and 24-month evaluation, closure rates did not show a statistically significant difference between the groups (P = 0.056 and P = 0.090, respectively). Preoperative and 1-month VCSS measurements did not show a statistically significant difference between groups (P > 0.05 for all comparisons). The 6-month, 12-month, and 24-month VCSS measurements of Group A were significantly higher than those in Group B. (P = 0.043, P = 0.009 and P = 0.002, respectively). CONCLUSIONS: Both RFA and CAC were found to be effective in the treatment of large-diameter GSV incompetency. The complication rates were similar between the 2 techniques. CAC had a shorter procedure time. Although the closure rates in the early postoperative period were better in the RFA group, long-term follow-up demonstrated similar patency rates. The functional results in the long-term follow-up were better in the RFA group.


Subject(s)
Cyanoacrylates , Saphenous Vein , Venous Insufficiency , Humans , Saphenous Vein/diagnostic imaging , Saphenous Vein/physiopathology , Saphenous Vein/surgery , Retrospective Studies , Female , Male , Venous Insufficiency/diagnostic imaging , Venous Insufficiency/surgery , Venous Insufficiency/physiopathology , Venous Insufficiency/therapy , Middle Aged , Treatment Outcome , Cyanoacrylates/adverse effects , Cyanoacrylates/administration & dosage , Time Factors , Adult , Aged , Radiofrequency Ablation/adverse effects , Endovascular Procedures/adverse effects , Tissue Adhesives/therapeutic use , Tissue Adhesives/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...